COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail.
Infect Disord Drug Targets
; 21(5): e270421186842, 2021.
Article
in English
| MEDLINE | ID: covidwho-1435859
ABSTRACT
The novel coronavirus disease (COVID-19) is on the rampage claiming over 297000 lives globally. Disease severity and mortality rates are higher in patients with underlying diabetes mellitus. Till date, there exists no effective vaccine or therapy against COVID-19. However, with limited clinical data, HCQ is being used for treatment and prophylaxis in patients with COVID-19. HCQ is also used as an anti-diabetic drug and has been approved in India as an adjunct to diet and exercise to improve glycemic control of patients with Type 2 Diabetes Mellitus (T2DM) on metformin and sulfonylurea combination in Type 2 Diabetes Mellitus (T2DM). Thus, although indiscriminate use of HCQ is fraught with danger, HCQ can be considered as a third-line add on anti-diabetic agent in people with T2DM amid the ongoing pandemic after having ruled out the contraindications to the use of this drug.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Diabetes Mellitus, Type 2
/
COVID-19
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Infect Disord Drug Targets
Journal subject:
Communicable Diseases
/
Drug Therapy
Year:
2021
Document Type:
Article
Affiliation country:
1871526520666201013160803
Similar
MEDLINE
...
LILACS
LIS